Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis

• Main Authors: Tina Bhutani (Author), John Koo (Author), Jayme Heim (Author), Neal Bhatia (Author), Jacob Mathew (Author), Thomas Ferro (Author), J. Gabriel Vasquez (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Plaque psoriasis is a chronic condition that may impact patients' work productivity. Tildrakizumab, an interleukin-23 p19 inhibitor, is approved for treatment of moderate-to-severe plaque psoriasis in adults. However, the effect of tildrakizumab treatment on work productiv...